The Future of CAR T-Cell Therapy: Insights From ASCO GI and EHA/EBMT

4 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/

In this video, Robert L. Ferris, MD, PhD, provides expert insight on the data released at the recent American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) and the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT) CAR T-cell Meeting.

Ferris dives into the groundbreaking data for a generally immunotherapy resistant set of cancers such as esophageal gastric cancer, and mismatch repair-deficient microsatellite unstable [MSI-high] colorectal cancers, presented at ASCO GI. Ferris also provides insight on the headway that chimeric antigen receptor (CAR) T-cell therapy is making in solid tumors expanding their use beyond hematologic malignancies.

Ferris is Lineberger distinguished professor executive director UNC Lineberger Comprehensive Cancer Center and chief of Oncology Services UNC Health System Chapel Hill, North Carolina.

#oncologycare #oncology #CART-celltherapy #EHA/EBMT #ASCOGI
Category
Oncology
Be the first to comment

Up Next